Efter 60 måneder var forekomsten af cancer, som ikke var hudcancer, signifikant højere i den patientgruppe, som fortsatte med at tage cyclosporin, end i den patientgruppe, hvor cyclosporin blev seponeret (henholdsvis 8, 4% over for 3, 8%).
By 60 months, the incidence of non-skin malignancies was significantly higher in the cohort who continued ciclosporin as compared with the cohort who had ciclosporin withdrawn (8.4% vs.